Coherus Oncology shares fall 17.91% after-hours as $50.1M public offering dilutes value.

Coherus Oncology (NASDAQ: CHRS) fell 17.91% in after-hours trading following the announcement of a $50.1 million public offering of 28.6 million shares priced at $1.75 each. The stock offering, described as a "follow-on" by multiple reports, triggered investor skepticism, with shares dropping 16.4% pre-market and further declining post-market. The move reflects the company’s need for capital amid ongoing financial challenges, including a -209.9% EBIT margin and limited liquidity. While the clinical supply agreement with Johnson & Johnson for a Phase 1b trial was noted, the immediate market reaction focused on the dilutive impact of the offering, which overshadowed other developments. Analysts highlighted that such capital raises often signal strategic but bearish signals, as investors perceive pressure on existing shareholders and question long-term value retention.